Investor Relations
ImpediMed Limited is a world leader in the development and distribution of medical devices using Bioimpedance Spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of human disorders and diseases.ImpediMed’s primary product range consists of a number of medical devices that enable surgeons, oncologists, radiation oncologists and therapists to clinically assess secondary lymphedema in breast cancer survivors. Pre-operative assessment can assist medical professionals to diagnose Lymphedema before the onset of symptoms and potentially before the condition progresses to irreversible forms. Irreversible Lymphedema becomes a lifelong management for patients and impairs their quality of life.
ImpediMed has the first medical devices with an FDA clearance in the United States for aiding in the clinical assessment, by health care providers, of unilateral lymphedema of the arm in women.
Note: ImpediMed devices are not intended to diagnose or predict lymphedema of an extremity
Stock Quote
Quotes delayed at least 20 minutesGlobal Headquarters
Unit 1, 50 Parker Court
Pinkenba, Qld 4008 Australia
Phone +61 (7) 3860-3700
Fax +61 (7) 3260-1225
ImpediMed Incorporated
5959 Cornerstone Court West
San Diego, CA 92121
Phone: +1 (858) 412 0200
Fax: +1 (858) 558 8540
Websites:
United States of America: http://www.impedimed.com
Australia / International: http://www.impedimed.com.au
Ticker Symbol: IPD
Exchange: ASX